<h1><br></h1><p><br></p><p>The vaccine, developed by researchers at the University of Oxford, has already entered its first human clinical trial, where it will be tested for safety and its ability to trigger an immune response. The Phase 1 study will involve 50 healthy adult volunteers before larger trials can be considered. While the rapid development has been hailed as a scientific milestone, experts stress that the vaccine has not yet been approved for public use.</p><p>The accelerated effort comes as health authorities battle the fastest-growing outbreak of the Bundibugyo strain of Ebola, a variant for which there is currently no licensed vaccine or specific treatment. The World Health Organization (WHO) says the outbreak has spread across several provinces in the Democratic Republic of the Congo and into neighbouring Uganda, making the need for effective vaccines increasingly urgent.</p><p>Researchers say the vaccine was developed using technologies and scientific knowledge gained during previous Ebola and COVID-19 vaccine programmes, allowing them to move from design to human testing in record time.</p><p>The WHO has welcomed the rapid progress but cautioned that clinical trials must demonstrate that the vaccine is both safe and effective before it can be deployed in outbreak settings. Until then, health authorities will continue to rely on surveillance, isolation of infected patients, contact tracing and strict infection prevention measures to contain the spread of the disease.</p><p>If the trials prove successful, the vaccine could become the first approved immunisation specifically targeting the Bundibugyo strain of Ebola, strengthening global preparedness against one of the world's deadliest viral diseases.</p><p>Photo credit: independent.co</p>